Bruker (NASDAQ:BRKR) Raised to "Strong-Buy" at The Goldman Sachs Group

Key Points

• Goldman Sachs upgraded Bruker to “strong buy” from “strong sell,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $57.
• Bruker reported quarterly EPS of $0.49, beating estimates of $0.38, although revenue of $838.5 million fell short of expectations. Revenue increased 5.2% year over year, and the company maintained fiscal 2026 EPS guidance of $2.10–$2.15.
• Bruker shares opened at $59.67, near their 52-week high of $65.30, with a market capitalization of approximately $9.09 billion. Insiders own 27.2% of the stock, while institutional investors own 79.52%.

Bruker (NASDAQ:BRKR - Get Free Report) was upgraded by The Goldman Sachs Group from a "strong sell" rating to a "strong-buy" rating in a research note issued to investors on Monday, Zacks reports.

BRKR has been the topic of several other reports. TD Cowen reissued a "hold" rating on shares of Bruker in a research note on Wednesday, July 15th. Leerink Partners increased their target price on shares of Bruker from $60.00 to $70.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. upped their price target on shares of Bruker from $55.00 to $65.00 and gave the company an "overweight" rating in a report on Monday, June 8th. Barclays raised their price objective on shares of Bruker from $53.00 to $60.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 24th. Finally, Wolfe Research began coverage on Bruker in a research report on Monday, June 1st. They set a "peer perform" rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bruker has a consensus rating of "Moderate Buy" and an average target price of $57.00.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $59.67 on Monday. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $9.09 billion, a PE ratio of -85.24, a price-to-earnings-growth ratio of 1.87 and a beta of 1.26. The firm's 50 day moving average price is $58.27 and its 200-day moving average price is $50.44. Bruker has a twelve month low of $30.09 and a twelve month high of $65.30.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. During the same period in the prior year, the company earned $0.32 earnings per share. The firm's revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts expect that Bruker will post 2.12 EPS for the current year.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company's stock, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Bruker

A number of large investors have recently made changes to their positions in the stock. Global Retirement Partners LLC acquired a new position in shares of Bruker in the second quarter valued at about $38,000. Essential Partners LLC purchased a new stake in Bruker in the first quarter valued at approximately $36,000. FNY Investment Advisers LLC acquired a new position in Bruker in the 2nd quarter worth approximately $60,000. IFP Advisors Inc lifted its stake in Bruker by 88.6% during the 2nd quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company's stock valued at $64,000 after acquiring an additional 498 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in Bruker by 532.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company's stock valued at $54,000 after acquiring an additional 1,263 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.